Multivalent Vaccines Market Report 2026

The multivalent vaccines market size has grown strongly in recent years. It will grow from $9.12 billion in 2025 to $9.97 billion in 2026 at a compound annual growth rate (CAGR) of 9.4%. The growth in the historic period can be attributed to global immunization initiatives, high burden of infectious diseases, government vaccination programs, improvements in cold chain infrastructure, public health awareness campaigns.

The multivalent vaccines market size is expected to see strong growth in the next few years. It will grow to $14.28 billion in 2030 at a compound annual growth rate (CAGR) of 9.4%. The growth in the forecast period can be attributed to rising focus on pandemic preparedness, increasing elderly population, growth in recombinant vaccine technologies, expansion of universal immunization coverage, increased healthcare funding. Major trends in the forecast period include rising demand for broad-spectrum immunization, increasing focus on combination vaccines, expansion of pediatric and geriatric vaccination programs, growing adoption of preventive healthcare measures, higher investment in vaccine r&d pipelines.

The increasing prevalence of infectious diseases is anticipated to boost the multivalent vaccines market in the future. Infectious diseases are conditions triggered by bacteria, viruses, fungi, or parasites that transmit via direct contact, tainted surfaces, airborne particles, or water. This surge stems from heightened global travel, which speeds up the spread of pathogens internationally. Multivalent vaccines aid in preventing diseases by providing protection against various pathogen strains in one shot, minimizing the requirement for multiple vaccinations and bolstering herd immunity. For example, in April 2024, TravelHealthPro - a UK travel health platform backed by the UK Health Security Agency - reported 2,004 malaria cases in the UK for 2023, compared to 1,369 imported cases the previous year. Thus, the growing rates of infectious diseases are fueling expansion in the multivalent vaccines market.

Major companies in the multivalent vaccines market are prioritizing the development of advanced pentavalent vaccines to broaden immunization coverage, streamline dosing schedules, and enhance public health results. Pentavalent vaccines are multivalent formulations that offer protection against five different pathogens in one dose, cutting down on injections, boosting compliance, and optimizing vaccine distribution efforts. For example, in December 2023, Panacea Biotec Ltd., an India-based biotech firm, introduced EasyFourPol, the world's first fully liquid pentavalent vaccine safeguarding against diphtheria, tetanus, pertussis, polio, and Haemophilus influenzae Type B. It features a ready-to-use format that skips preparation for healthcare providers, cuts clinic visits and immunization expenses, and reduces environmental footprint by decreasing reliance on multiple vials, syringes, and packaging.

In February 2024, AstraZeneca plc, a UK-based pharmaceutical firm, bought Icosavax Inc. for $1.1 billion. This deal bolsters AstraZeneca’s vaccine lineup with Icosavax’s advanced RSV candidate, IVX-A12, and broadens the company’s footprint in the respiratory vaccine sector. It also boosts AstraZeneca’s R&D strengths via Icosavax’s proprietary protein virus-like particle (VLP) technology, which supports multivalent vaccines against respiratory viruses. Icosavax Inc. is a US-based biotech firm focused on a protein VLP platform for developing multivalent vaccines.

Major companies operating in the multivalent vaccines market are Pfizer Inc., Merck & Co. Inc., Sanofi SA, GlaxoSmithKline plc, Novartis AG, CSL Seqirus, Zydus Lifesciences Limited, Sinovac Biotech Ltd., GC Biopharma Corp., Serum Institute of India Pvt. Ltd., Indian Immunologicals Ltd., Bavarian Nordic, Panacea Biotec Ltd., VBI Vaccines Inc., WestVac Biopharma Co. Ltd., Emergent BioSolutions Inc., Moderna Inc., BioNTech SE, Abbott Laboratories, Boehringer Ingelheim International GmbH.

North America was the largest region in the multivalent vaccines market in 2025. The regions covered in the multivalent vaccines market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the multivalent vaccines market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the multivalent vaccines market by increasing the cost of imported biologic raw materials, antigens, and specialized manufacturing equipment used in complex vaccine production. These effects are most pronounced in developing regions that rely heavily on imported inputs for large scale immunization programs. Rising tariff related expenses have placed pressure on public health budgets and vaccine procurement planning. In some markets, this has contributed to delays in vaccine tenders and rollout schedules. However, tariffs are also encouraging domestic vaccine production, technology transfer initiatives, and stronger local supply chains to improve long term vaccine availability.

The multivalent vaccines market research report is one of a series of new reports that provides multivalent vaccines market statistics, including multivalent vaccines industry global market size, regional shares, competitors with a multivalent vaccines market share, detailed multivalent vaccines market segments, market trends and opportunities, and any further data you may need to thrive in the multivalent vaccines industry. This multivalent vaccines market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Multivalent vaccines are formulated to safeguard against multiple strains or types of one pathogen, or even several distinct pathogens, all in a single shot. They incorporate antigens from different strains or diseases to build immunity against numerous targets at once, delivering wider protection than monovalent vaccines that target just one strain or pathogen.

The primary categories of multivalent vaccines include conjugate vaccines, inactivated and subunit vaccines, live attenuated vaccines, toxoid vaccines, and recombinant vaccines. Conjugate vaccines connect a less potent antigen to a more robust one, boosting immune detection and efficacy, especially against bacterial infections. They target conditions like influenza, pneumonia, hepatitis, meningitis, and rotavirus, delivered via routes such as oral or injectable. These vaccines serve multiple age demographics, including children, adults, and seniors, and are available through channels like hospital pharmacies, retail pharmacies, and online pharmacies.

The multivalent vaccines market consists of sales of bivalent vaccines, trivalent vaccines, and polyvalent vaccines. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.